Pharmaceutical - Diabetes, Pharmaceutical

Filter

Current filters:

DiabetesPharmaceutical

Popular Filters

1 to 25 of 401 results

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

24-09-2014

UK-based pharma major AstraZeneca has announced new research showing that Byetta (exenatide) added to…

AstraZenecaByettaDiabetesGlucagonPharmaceuticalResearchUK

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

19-09-2014

The global burden of diabetes is growing fast with an astonishing 10% of global healthcare expense spent…

DenmarkDiabetesEuropeMexicoNovo NordiskPharmaceuticalResearchRyzodegTresibaXultophy

FDA approves Lilly’s Trulicity to treat type 2 diabetes

FDA approves Lilly’s Trulicity to treat type 2 diabetes

19-09-2014

The US Food and Drug Administration yesterday approved pharma major Eli Lilly’s Trulicity (dulaglutide),…

BydureonDiabetesdulaglutideEli LillyPharmaceuticalRegulationTanzeumTrulicityUSAVictoza

First Ph III data in Japanese patients for Merck’s omarigliptin for type 2 diabetes

18-09-2014

US pharma giant Merck & Co has announced the presentation of the first data from the Phase III clinical…

DiabetesJapanMerck & CoomarigliptinPharmaceuticalRegulationResearch

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

16-09-2014

Danish diabetes care giant Novo Nordisk announced positive new data from the BEGIN YOUNG 1 trial today,…

DiabetesNovo NordiskPharmaceuticalResearchTresiba

Empagliflozin/linagliptin combo shows sustained reduction in blood glucose in Ph III

16-09-2014

Family-owned German pharma major Boehringer Ingelheim and US partner Eli Lilly have presented results…

Boehringer IngelheimDiabetesEli LillyempagliflozinlinagliptinPharmaceuticalResearch

EU approval for Boehringer and Lilly’s insulin glargine biosimilar

EU approval for Boehringer and Lilly’s insulin glargine biosimilar

10-09-2014

The European Commission granted marketing authorization for US drug major Eli Lilly and family-owned…

AbasriaBasaglarBiosimilarsBoehringer IngelheimDiabetesEli LillyEuropeInsulinLantusPharmaceuticalRegulationSanofi

The FDA publishes Novo Nordisk briefing documents ahead of Saxenda Advisory Committee meeting

The FDA publishes Novo Nordisk briefing documents ahead of Saxenda Advisory Committee meeting

09-09-2014

The US Food and Drug Administration has published briefing documents on Danish insulin giant Novo Nordisk’s…

Anti-diabetic drugsDiabetesliraglutideNovo NordiskPharmaceuticalRegulationTreatment of obesityUSA

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

04-09-2014

US pharma major Eli Lilly has released additional clinical data showing superiority for its diabetes…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

Mexico first country to launch Novo Nordisk’s Ryzodeg

Mexico first country to launch Novo Nordisk’s Ryzodeg

01-09-2014

Danish diabetes care giant Novo Nordisk today announced that Mexico has become the first country in the…

DiabetesMarkets & MarketingMexicoNovo NordiskPharmaceuticalRyzodeg

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

31-08-2014

Japan’s largest drugmaker Takeda Pharmaceutical and US pharma major Eli Lilly have failed in their…

ActosDiabetesEli LillyFinancialLegalPharmaceuticalTakeda PharmaceuticalUSA

UK NICE wants more info on type 2 diabetes drug Jardiance

UK NICE wants more info on type 2 diabetes drug Jardiance

28-08-2014

In a new draft guidance issued today, the UK drugs watchdog the National Institute for Health and Care…

Boehringer IngelheimDiabetesEli LillyJardiancePharmaceuticalPricingRegulationUK

Call for Indian govt to bring more essential drugs under price control from NGOs

Call for Indian govt to bring more essential drugs under price control from NGOs

22-08-2014

Non-governmental organizations in India have jointly issued a letter calling on the country’s government…

Cardio-vascularDiabetesIndiaNational Pharmaceuticals Pricing AuthorityPharmaceuticalPoliticsPricing

Insulin offers new hope for the treatment of acute pancreatitis

22-08-2014

Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting…

DiabetesInflammatory diseasesPancreas disordersPharmaceuticalResearchUK

Tentative FDA approval for Lilly and Boehringer Ingelheim's Basaglar

Tentative FDA approval for Lilly and Boehringer Ingelheim's Basaglar

19-08-2014

The US Food and Drug Administration yesterday granted tentative approval for Basaglar (insulin glargine…

AbasriaBasaglarBiosimilarsBoehringer IngelheimDiabetesEli LillyInsulin Glargine [rDNA origin] InjectionLantusPharmaceuticalRegulationUSA

Novo Nordisk accepts fine from Danish public prosecutor over financial disclosure

Novo Nordisk accepts fine from Danish public prosecutor over financial disclosure

18-08-2014

Danish insulin giant Novo Nordisk has accepted a fine of 500,000 kroner ($89,735), imposed by the Public…

CopenhagenDanish Financial Supervisory AuthorityDenmarkDiabetesFinancialNovo NordiskPharmaceutical

Sanofi in $925 million deal to commercialize MannKind’s Afrezza

Sanofi in $925 million deal to commercialize MannKind’s Afrezza

11-08-2014

French pharma major Sanofi has entered into a worldwide exclusive licensing agreement with the USA’s…

AfrezzaDiabetesGlobalInsulin therapyLicensingMannKindPeptide hormonesPharmaceuticalSanofi

Positive new Ph III data with Novo Nordisk’s Xultophy

Positive new Ph III data with Novo Nordisk’s Xultophy

11-08-2014

Positive new pivotal Phase III data about Xultophy (insulin degludec/liraglutide), formerly known as…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchXultophy

FDA approves Janssen’s Invokamet for diabetes

09-08-2014

The US Food and Drug Administration has approved US health care giant Johnson & Johnson subsidiary Janssen…

DiabetesInvokametInvokanaJanssenJohnson & JohnsonPharmaceuticalRegulationUSA

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

08-08-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGerman Institute for Quality and EfficiencyGermanyNovo NordiskPharmaceuticalPricingRegulationTresiba

1 to 25 of 401 results

Back to top